Oral antibiotics attenuate bowel segment reversal-induced systemic inflammatory response and body weight loss in massively bowel-resected rats.
BACKGROUND
Using a massively bowel-resected rat model, our previous study demonstrated that small bowel segment reversal stimulates jejunal hyperplasia but may also increase the possibility of bacterial translocation and the elevation of circulating white blood cells and serum interleukin-6 that may reduce the whole-body anabolism. The aim of this study is to investigate whether oral antibiotics might attenuate the inflammatory responses and might therefore facilitate the beneficial effects of bowel segment reversal.


METHODS
Male Wistar rats (approximately 270 g) underwent a 70% small bowel resection with (REV group) or without (CON group) a 3-cm small bowel segment reversal, or underwent a sham operation (SHAM group). After surgeries, half of the animals in the REV group were given oral clindamycin plus amoxicillin (50 plus 50 mg/kg/d, ANT group) for 3 weeks.


RESULTS
Oral antibiotics administration significantly attenuated the decreases in feeding efficiency (g of body weight/100 kcal diet) and increases in the circulation of white blood cells, serum nitric oxide, and interleukin-6 (1-way ANOVA, p < .05), which are associated with bowel segment reversal. In addition, antibiotics significantly increased serum concentrations of insulin-like growth factor-I, significantly decreased the total numbers of bacteria in the intestine, and tended to reduce the extent of jejunal hyperplasia in rats with bowel segment reversal.


CONCLUSIONS
Our results suggest that oral antibiotics may be used as an adjuvant to attenuate the inflammatory responses and to enhance the anabolic responses in massively bowel-resected patients with bowel segment reversal.
Lee
Chien-Hsing
CH
Division of Pediatric Surgery, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.
Lo
Hui-Chen
HC
Chou
Ming-Chih
MC
Tsai
Huei-Ru
HR
D000222:Adaptation, Physiological / Q000187:drug effects / Q000502:physiology; D000658:Amoxicillin / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D018988:Bacterial Translocation / Q000187:drug effects*; D002981:Clindamycin / Q000494:pharmacology; D004435:Eating; D006965:Hyperplasia / Q000517:prevention & control*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D015850:Interleukin-6 / Q000097:blood; D007421:Intestine, Small / Q000473:pathology* / Q000601:surgery*; D007958:Leukocyte Count; D008297:Male; D009569:Nitric Oxide / Q000097:blood; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012778:Short Bowel Syndrome / Q000150:complications* / Q000601:surgery; D015431:Weight Loss / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D015850:Interleukin-6; D009569:Nitric Oxide; D002981:Clindamycin; D007334:Insulin-Like Growth Factor I; D000658:Amoxicillin